BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND SSX1, MGC5162, 6756, ENSG00000126752, RP11-552E4_1, SSRC, MGC150425, Q16384
89407 results:

  • 1. Comprehensive Analysis of the Immunosuppressive Function of Regulatory T Cells in Human Hepatocellular Carcinoma Tissues.
    Ge J; Chen J; Shen Q; Zheng X; Chen X; Shi L; Chen L; Xu B
    Cancer Control; 2024; 31():10732748241251580. PubMed ID: 38712609
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Applications of Pyrrole and Pyridine-based Heterocycles in cancer Diagnosis and Treatment.
    Tyagi R; Yadav K; Srivastava N; Sagar R
    Curr Pharm Des; 2024; 30(4):255-277. PubMed ID: 38711394
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
    Chang JY; Ruff SM; Cloyd JM
    Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Large enrichments in fatty acid
    Maloney AE; Kopf SH; Zhang Z; McFarlin J; Nelson DB; Masterson AL; Zhang X
    Proc Natl Acad Sci U S A; 2024 May; 121(20):e2310771121. PubMed ID: 38709917
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Nanoparticle/Engineered Bacteria Based Triple-Strategy Delivery System for Enhanced Hepatocellular Carcinoma cancer Therapy.
    Yang M; Chen W; Gupta D; Mei C; Yang Y; Zhao B; Qiu L; Chen J
    Int J Nanomedicine; 2024; 19():3827-3846. PubMed ID: 38708180
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Predicting effect of anti-PD-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
    Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
    Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Contemporary trends and outcomes after liver transplantation and resection for intrahepatic cholangiocarcinoma.
    Howell TC; Rhodin KE; Shaw B; Bao J; Kanu E; Masoud S; Bartholomew AJ; Gao Q; Anwar IJ; Ladowski JM; Nussbaum DP; Blazer DG; Zani S; Allen PJ; Barbas AS; Lidsky ME
    J Gastrointest Surg; 2024 May; 28(5):738-745. PubMed ID: 38704208
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Long-term survival after hepatic resection for colorectal liver metastases: a single-center study in Iran.
    Pourfaraji SM; Moghadam MN; Moradi AM; Shirmard FO; Mohammadzadeh N; Jafarian A
    BMC Surg; 2024 May; 24(1):131. PubMed ID: 38702645
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
    Lacombe K; Moh R; Chazallon C; Lemoine M; Sylla B; Fadiga F; Le Carrou J; Marcellin F; Kouanfack C; Ciaffi L; Sartre MT; Sida MB; Diallo A; Gozlan J; Seydi M; Cissé V; Danel C; Girard PM; Toni TD; Minga A; Boyer S; Carrieri P; Attia A;
    Sci Rep; 2024 May; 14(1):10244. PubMed ID: 38702350
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prevalence and risk of nonalcoholic fatty liver disease among adult psoriatic patients: A systematic review, meta-analysis, and trial sequential analysis.
    Hu J; Shao Y; Gui C; Xiao Y; Li L; Li Z
    Medicine (Baltimore); 2024 May; 103(18):e38007. PubMed ID: 38701269
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Feng J; Zhao Y; Zhai L; Zhou J
    Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Role of CENPF and NDC80 in the rehabilitation nursing of hepatocellular carcinoma and cirrhosis: An observational study.
    Jia W; Wu Q; Li R; Hou S; Kang C
    Medicine (Baltimore); 2024 May; 103(18):e37984. PubMed ID: 38701255
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Heavy metal levels and human health risk implications associated with fish consumption from the lower Omo river (Lotic) and Omo delta lake (Lentic), Ethiopia.
    Kotacho AA; Yimer GT; Sota SS; Berego YS
    PeerJ; 2024; 12():e17216. PubMed ID: 38699190
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
    Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
    Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Construction and validation of "WCH-nomogram" for predicting the prognosis after resection of colorectal liver metastases.
    Jiang C; Liu W; Jin Z; Lan L; Xu L; Du A; Peng S; Zeng Y; Wang H; Liao M; Zhou J
    Cancer Med; 2024 May; 13(9):e7222. PubMed ID: 38698687
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
    Xiong KG; Ke KY; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
    World J Surg Oncol; 2024 May; 22(1):117. PubMed ID: 38698475
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Evaluation of TikTok videos on acute pancreatitis: content quality and reliability analysis.
    Mao T; Zhao X; Jiang K; Yang J; Xie Q; Fu J; Du B; Lei Z; Gao F
    BMC Public Health; 2024 May; 24(1):1216. PubMed ID: 38698404
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Predictive factors of 90-day mortality after curative hepatic resection for hepatocellular carcinoma: a western single-center observational study.
    Vaghiri S; Lehwald-Tywuschik N; Prassas D; Safi SA; Kalmuk S; Knoefel WT; Dizdar L; Alexander A
    Langenbecks Arch Surg; 2024 May; 409(1):149. PubMed ID: 38698255
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4471.